Dr. Alter Discusses Provenge MOA and Tolerability

Robert S. Alter, MD
Published: Friday, Dec 02, 2011

Robert S. Alter, MD, co-chief, Urologic Oncology, John Theurer Cancer Center, discusses the mechanism of action (MOA) and tolerability of the immunotherapy Provenge (sipuleucel-T) in men with asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer.

The product of the Provenge vaccine stimulates the immune system by activating t-cells to recognize prostate cancer cells. The vaccine is created from the patient’s own cells, which prevents it from being rejected by the body.

Provenge provides a well-tolerated active therapy. The response varies from patient-to-patient ranging from nominal to prolonged. A survival benefit for Provenge was derived from several controlled trials. The median survival benefit from the vaccine is 25.8 months, compared to 21.7 in control groups.

Robert S. Alter, MD, co-chief, Urologic Oncology, John Theurer Cancer Center, discusses the mechanism of action (MOA) and tolerability of the immunotherapy Provenge (sipuleucel-T) in men with asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer.

The product of the Provenge vaccine stimulates the immune system by activating t-cells to recognize prostate cancer cells. The vaccine is created from the patient’s own cells, which prevents it from being rejected by the body.

Provenge provides a well-tolerated active therapy. The response varies from patient-to-patient ranging from nominal to prolonged. A survival benefit for Provenge was derived from several controlled trials. The median survival benefit from the vaccine is 25.8 months, compared to 21.7 in control groups.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x